BMO: Scholar Rock Holds Opportunity In Multibillion-Dollar Spinal Muscular Atrophy Market
Analysts See 100% Upside To Rigel After Tavalisse Approval
BMO Capital Markets: BioXcel's AI Platform Provides Partially Derisked Drug Candidates
VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO
Do Kim Recent News
Ionis Pharma's Target Lifted To $68 Following More Favorable Spinraza Ramp Estimates
Here's Why Retrophin's DUET Data Pushes Upside To 129%
BMO Analysts Initiate Coverage On Rigel Pharma, Seeing 65% Upside
Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 Takeout Price
BMO Downgrades Ionis Pharma After Platelet Concerns Spill Over To Volanesorsen